1. Home
  2. IMAB vs CODA Comparison

IMAB vs CODA Comparison

Compare IMAB & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • CODA
  • Stock Information
  • Founded
  • IMAB 2014
  • CODA 1994
  • Country
  • IMAB United States
  • CODA United States
  • Employees
  • IMAB 220
  • CODA N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • CODA Industrial Machinery/Components
  • Sector
  • IMAB Health Care
  • CODA Industrials
  • Exchange
  • IMAB Nasdaq
  • CODA Nasdaq
  • Market Cap
  • IMAB 79.9M
  • CODA 92.5M
  • IPO Year
  • IMAB 2020
  • CODA N/A
  • Fundamental
  • Price
  • IMAB $0.99
  • CODA $7.82
  • Analyst Decision
  • IMAB Strong Buy
  • CODA Strong Buy
  • Analyst Count
  • IMAB 3
  • CODA 1
  • Target Price
  • IMAB $8.00
  • CODA $11.00
  • AVG Volume (30 Days)
  • IMAB 274.1K
  • CODA 29.4K
  • Earning Date
  • IMAB 03-13-2025
  • CODA 03-17-2025
  • Dividend Yield
  • IMAB N/A
  • CODA N/A
  • EPS Growth
  • IMAB N/A
  • CODA 14.29
  • EPS
  • IMAB N/A
  • CODA 0.32
  • Revenue
  • IMAB $3,313,984.00
  • CODA $20,316,161.00
  • Revenue This Year
  • IMAB N/A
  • CODA $22.31
  • Revenue Next Year
  • IMAB N/A
  • CODA $12.02
  • P/E Ratio
  • IMAB N/A
  • CODA $24.41
  • Revenue Growth
  • IMAB N/A
  • CODA 4.98
  • 52 Week Low
  • IMAB $0.84
  • CODA $5.41
  • 52 Week High
  • IMAB $2.08
  • CODA $9.89
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.19
  • CODA 41.62
  • Support Level
  • IMAB $1.03
  • CODA $7.75
  • Resistance Level
  • IMAB $1.10
  • CODA $8.13
  • Average True Range (ATR)
  • IMAB 0.06
  • CODA 0.34
  • MACD
  • IMAB -0.01
  • CODA -0.05
  • Stochastic Oscillator
  • IMAB 7.58
  • CODA 7.22

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.

Share on Social Networks: